(Q38184929)

30 August 2017

Effects of incretin-based therapy in patients with heart failure and myocardial infarction (English)

1 reference

30 August 2017

0 references

Nasser Mikhail

1

1 reference

30 August 2017

4 February 2014

1 reference

30 August 2017

1 reference

30 August 2017

47

1 reference

30 August 2017

1

1 reference

30 August 2017

21-28

1 reference

https://scigraph.springernature.com/pub.10.1007/s12020-014-0175-4

30 August 2017

0 references

cites work

Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0175-4

Chronic glucagon-like peptide-1 infusion sustains left ventricular systolic function and prolongs survival in the spontaneously hypertensive, heart failure-prone rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0175-4

Tissue-specific expression of the human receptor for glucagon-like peptide-I: brain, heart and pancreatic forms have the same deduced amino acid sequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0175-4

Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0175-4

Initial experience with GLP-1 treatment on metabolic control and myocardial function in patients with type 2 diabetes mellitus and heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0175-4

Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0175-4

Cardiovascular and metabolic effects of 48-h glucagon-like peptide-1 infusion in compensated chronic patients with heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0175-4

Effects of intravenous exenatide in type 2 diabetic patients with congestive heart failure: a double-blind, randomised controlled clinical trial of efficacy and safety.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0175-4

Effects of intravenous glucagon-like peptide-1 on glucose control and hemodynamics after coronary artery bypass surgery in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0175-4

Exenatide reduces final infarct size in patients with ST-segment-elevation myocardial infarction and short-duration of ischemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0175-4

Effect of additional treatment with EXenatide in patients with an Acute Myocardial Infarction: the EXAMI study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0175-4

Cardioprotective effects of exenatide in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of exenatide myocardial protection in revascularization study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0175-4

DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0175-4

The relationships of left ventricular ejection fraction, end-systolic volume index and infarct size to six-month mortality after hospital discharge following myocardial infarction treated by thrombolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0175-4

Exenatide alters myocardial glucose transport and uptake depending on insulin resistance and increases myocardial blood flow in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0175-4

Exenatide improves endothelial function assessed by flow mediated dilation technique in subjects with type 2 diabetes: results from an observational research

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0175-4

Metabolic effects of short-term GLP-1 treatment in insulin resistant heart failure patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0175-4

Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0175-4

Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0175-4

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0175-4

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0175-4

Investigational anti-hyperglycemic agents: the future of type 2 diabetes therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0175-4

Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0175-4

Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure

21 January 2018

1 reference

12 December 2020

Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis.

1 reference

12 December 2020

Cardioprotection against ischaemia induced by dobutamine stress using glucagon-like peptide-1 in patients with coronary artery disease

1 reference

12 December 2020

Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes

1 reference

12 December 2020

Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting

1 reference

12 December 2020

10.1007/S12020-014-0175-4

Identifiers

DOI

1 reference

30 August 2017

1 reference

PubMed ID

24493030